Evidence map›Paper›PMID 31581292›Full record

ArticleThe Journal of infectious diseases2020

Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains.

Andrew D Redd, Nicole A Doria-Rose, Joshua A Weiner, Martha Nason, Matthew Seivers, Stephen D Schmidt, Oliver Laeyendecker, Craig Martens, Daniel Bruno, Brandon F Keele and 9 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Andrew D ReddLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Joshua A WeinerDartmouth College, Hanover, New Hampshire, USA.
Martha NasonBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Matthew SeiversDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stephen D SchmidtVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Oliver LaeyendeckerLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Craig MartensGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Daniel BrunoGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Fredrick, Maryland, USA.
Nagarajan RajuDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ivelin S GeorgievDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Susanna L LamersBioInfoExperts, Thibodaux, Louisiana, USA.
Jacquie AstemborskiDepartment of Epidemiology, Bloomberg of School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Gregory D KirkDepartment of Epidemiology, Bloomberg of School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Margaret E AckermanDartmouth College, Hanover, New Hampshire, USA.
Shruti H MehtaDepartment of Epidemiology, Bloomberg of School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Thomas C QuinnLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USJohns Hopkins Medicine · USJohns Hopkins University · USDartmouth College · USNational Institute of Allergy and Infectious Diseases · USBloomberg (United States) · USFrederick National Laboratory for Cancer Research · USVanderbilt Health · USVanderbilt University · US

Funding

The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1R01AI131722 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2017 to 2021
$4.5M
Directing Antibody Effector Activity via Controlled IgG Subclass SwitchingR01AI131975 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2017 to 2020
$2.6M
Patient-Oriented Research and Mentorship in HIV and Non-Communicable DiseasesK24AI118591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2015 to 2019
$766k
NIAID NIH HHS K24 AI118591NIAID NIH HHS R01 AI131722NIAID NIH HHS R01 AI131975NIDA NIH HHS R01 DA012568NIDA NIH HHS U01 DA036297
6 · The paper itself

Abstract

backgroundMultiple factors influence the human immunodeficiency virus (HIV) antibody response produced during natural infection, leading to responses that can vary in specificity, strength, and breadth.

methodsPeople who inject drugs identified as recently infected with HIV (n = 23) were analyzed for clustering of their viral sequences (genetic distance, <2%). Longitudinal antibody responses were identified for neutralizing antibody (Nab) potential, and differences in antibody subclass, specificity, and Fc receptor ligation using pseudovirus entry and multiplexed Fc array assays, respectively. Responses were analyzed for differences between subject groups, defined by similarity in the sequence of the infecting virus.

resultsViral sequences from infected individuals were grouped into 3 distinct clusters with 7 unclustered individuals. Subjects in cluster 1 generally had lower antibody response magnitudes, except for antibodies targeting the V1/V2 region. Subjects in clusters 2 and 3 typically had higher antibody response magnitudes, with the Fv specificity of cluster 2 favoring gp140 recognition. NAb responses differed significantly between clusters for 3 of 18 pseudoviruses examined (P < .05), but there were no differences in overall NAb breadth (P = .62). DISCUSSION: These data demonstrate that individuals infected with similar viral strains can generate partially similar antibody responses, but these do not drastically differ from those in individuals infected with relatively unrelated strains.

Indexed as

EpidemicsAcquired Immunodeficiency SyndromeAdultAntibodies, NeutralizingBaltimoreBase SequenceCluster AnalysisFemaleFollow-Up StudiesHIV-1HIV AntibodiesHIV Envelope Protein gp41HumansLongitudinal StudiesMalePhylogenyAntibodies, Neutralizinggp41 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp41pol Gene Products, Human Immunodeficiency Virusantibody developmentcluster linkageHIVneutralizing antibodypeople who inject drugs

Identifiers

PMID31581292
PMCPMC7026888
OpenAlexW2977559283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.